Company Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.
The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.
The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas.
Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
| Country | United States |
| Founded | 2007 |
| IPO Date | Feb 12, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 134 |
| CEO | Michael Graves |
Contact Details
Address: 50 Tice Boulevard, Suite 315 Woodcliff Lake, New Jersey 07677 United States | |
| Phone | 201-326-5300 |
| Website | eagleus.com |
Stock Details
| Ticker Symbol | EGRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000827871 |
| CUSIP Number | 269796108 |
| ISIN Number | US2697961082 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Graves | Interim Principal Executive Officer and Executive Chairman of the Board |
| Steven B. Ratoff | Interim Chief Financial Officer, Principal Accounting Officer and Director |
| Daniel O'Connor | Executive Vice President, Chief Strategy Officer and Head of Corporate Development |
| Dr. Valentin R. Curt M.D. | Senior Vice President of Clinical Drug Development |
| Dr. Gaozhong Zhu Ph.D. | Senior Vice President of Pharmaceutical Development |
| Debra M. Hussain | Senior Vice President and Head of Commercial |
| Reed McClung | Executive Vice President of Oncology Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | 8-K | Current Report |
| Mar 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 18, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 8, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 8-K | Current Report |